The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monthly Archives: July 2010

FedDev Ontario is Feeding $45 million Through NRC-IRAP to Support SMB Innovation

During a visit to Sernova (TSXV: SVA) today, Gary Goodyear* announced that $45 million of FedDev Ontario money will be deployed through the NRC’s Industrial Research Assistance Program (IRAP). IRAP has been a relatively effective vehicle for funding life science companies and has taken a prominent role since having been allocated $200 million in the 2009 federal [...]

Monday Biotech Deal Review: July 26, 2010

Things were interesting for Forbes Medi-Tech (or at least its creditors), which saw a new bidder emerge for its assets. A few placements and other deals closed, some lower than expected. See who made it through the heat without wilting this week

This Week in the Twitterverse

Here’s some reading for the weekend from our Twitter stream on @crossborderbio: CIHR and Genome Canada will each contribute up to $2m for applications of next-gen sequencing to childhood diseases http://bit.ly/bt3rQH RT @FierceBiotech: Sanofi-Aventis Approaches Genzyme for Deal. http://bit.ly/cycl2Q RT @CLSD: What is the the next bio frontier in Canada? Our North! Nunavut bio-prospecting deal could [...]

Q2 Canadian Healthcare Review Shows Biotech Financing Weakness but Some M&A and Regulatory Wins

Data in the Q2 2010 Canadian Healthcare Review from the Equicom Group (co-authored by James Smith, Vice President Healthcare at Equicom and myself) shows a continuation of the weakness in biotech financing that was outlined in last week’s Toronto presentation of Ernst & Young’s Beyond Borders global biotech report. The public Canadian development stage companies raised [...]

Monday Biotech Deal Review: July 19, 2010

Lots of deals this week. Some good news, some bad news. On the good news front, a steady volume of securities and M&A activity is continuing through the summer; and one Canadian firm benefits from the U.S. Defense Departments exploration of RNAi products as anti-virals. On the other hand front, though, a licensing option expired, a liquidation proceeded [...]

This Week in the Twitterverse

Here’s some reading for the weekend from our Twitter stream on @crossborderbio: via @Michael_Gilman and @pearlf, great advice on running effective board mtgs http://j.mp/bkbjbh  U.S. Defense Dept Transformational Medical Tech program funds 2 RNAi projects: BC’s Tekmira http://bit.ly/cpOa8U & AVI http://bit.ly/ckCCxU  RT @FiercePharma: Reuters: Glaxo, Pfizer JV opens HIV pipeline to generic cos. http://bit.ly/adLi9x  RT @genomicslawyer: [...]

E&Y Beyond Borders Biotech Report 2010 — Canadian Biotech Data

I went to Ernst & Young‘s Toronto presentation of this year’s Beyond Borders global biotech report (pdf) this morning. The report is a retrospective of 2009, so many of the data points and trends reflect things you’ve seen already; but as always, I’d encourage you to read the whole thing for good synthesis and commentary. E&Y’s [...]

Monday Biotech Deal Review: July 12, 2010

This week saw several interesting deals, including an $85+ million exit for Sentinelle, some “bio-bucks” made good for Cipher, a licensing deal for Amorfix’s vCJD technology, a $10 million malaria deal for BC-based Artepharm and a new name (Medwell Capital) to go along with BioMS’ new business model.

This Week in the Twitterverse

As you may have surmised (from my out-of-office email or from my attempts to get the attention of Delta’s customer service tweeps) I was out of town this week. Still, here’s some weekend reading for you from our Twitter stream @crossborderbio: RT @dgmacarthur: July 12 is your last chance to comment on NIH’s planned genetic [...]

Monday Biotech Deal Review: July 5, 2010

Not a bad week for deals, considering the holiday weekend in both Canada and the U.S.. Response Biomedical placed a PIPE with OrbiMed funds, CTI did a follow-on round in Zymeworks and LAB Research took an equity line. Plus a companion diagnostic deal from Aeterna, just as I’m planning for Diagnostics Asia in August. The week’s [...]

This Week in the Twitterverse

Here’s some reading for the weekend from our Twitter stream on @crossborderbio: RT @IBMResearch: Roche and IBM Collaborate to Develop Nanopore-Based DNA Sequencing Technology – http://cot.ag/9vbj8l  RT @CBCHealth: Chalk River reactor to restart in July: AECL http://bit.ly/d66r72  RT @ogilvyrenault: Ogilvy Renault’s Rick Sutin quoted in Financial Post article on TSX/TSXV’s strength in cleantech http://bit.ly/cFAXr2  RT @markrmcqueen [...]

Follow

Get every new post delivered to your Inbox.

Join 76 other followers